Day: July 23, 2020

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESAll dollar amounts are presented in Canadian dollars unless otherwise noted.YERINGTON, Nev., July 23, 2020 (GLOBE NEWSWIRE) — Nevada Copper Corp. (TSX: NCU) (“Nevada Copper” or the “Company’’) is pleased to announce that it has filed and obtained a receipt for a final short form prospectus with the securities regulatory authorities in each of the provinces of Canada, except Quebec, in connection with its previously announced offering of 643,713,553 units of the Company (the “Units”) at a price of $0.15 per Unit for aggregate gross proceeds of approximately $97 million (the “Offering”).Each Unit consists of one common share of Nevada Copper (a “Common Share”) and one-half of one Common Share purchase warrant (each whole Common Share...

WESTLAKE, Texas, July 23, 2020 (GLOBE NEWSWIRE) — Goosehead Insurance, Inc. (“Goosehead” or the “Company”) (NASDAQ: GSHD), announced that it will report its second quarter 2020 results after the market close on Thursday, July 30, 2020.The company will hold a conference call to discuss results at 4:30 PM ET on that day. The dial-in number for the conference call is (855) 327-6837 (toll-free) or (631) 891-4304 (international). Please dial the number 10 minutes prior to the scheduled start time. A live webcast of the conference call will also be available on Goosehead’s investor relations website at http://ir.gooseheadinsurance.com.A webcast replay of the call will be available at http://ir.gooseheadinsurance.com for one year following the call.About GooseheadGoosehead (NASDAQ: GSHD) is a rapidly growing and innovative independent...

NASHVILLE, Tenn., July 23, 2020 (GLOBE NEWSWIRE) — CapStar Financial Holdings, Inc. (“CapStar”, the “Company”) (NASDAQ: CSTR), the parent company of CapStar Bank, and Gaylon Lawrence jointly announced today an agreement to facilitate a strong and supportive relationship to the benefit of all stakeholders and resolve the outstanding litigation between the parties.“We look forward to engaging with Gaylon and building a productive and mutually beneficial relationship,” said Timothy K. Schools, CapStar President and CEO.  “CapStar’s board appreciates Gaylon’s substantial investment and support as we work to maximize our potential.  CapStar is a young company and well positioned for continued success, having outstanding employees, industry-leading client delivery and service, and strong geographic positioning, all of which has situated...

—29% growth in deposits of Banco Azteca Mexico to Ps.177,335 million, generates solid prospects for the financial business——Ratio of deposits to gross portfolio of 1.9 times, is outstanding in the sector, and consolidates firm growth expectation for the Bank, with optimal funding cost— —Capitalization index of Banco Azteca of 15.32%, shows remarkable financial strength—MEXICO CITY, July 23, 2020 (GLOBE NEWSWIRE) — Grupo Elektra, S.A.B. de C.V. (BMV: ELEKTRA*; Latibex: XEKT), Latin America’s leading specialty retailer and financial services company, and the largest non-bank provider of cash advance services in the United States, today announced second quarter 2020 financial results.Second Quarter ResultsConsolidated revenue was Ps.28,154 million in the period, in comparison with Ps.28,762 million for the same quarter of the previous...

第 2/3 期研究過程已在巴西和墨西哥啟動 全球第 2/3 期 opaganib 用於嚴重 COVID-19 患者的研究已獲批准在英國及俄羅斯展開 將於本月開始在多達 40 個臨床中心為計劃納入 270 名受試者 預計於 2020 年第 4 季可能提交緊急用途申請 預計將於 8 月完成嚴重 COVID-19 美國第 2 階段平行研究的納入工作以色列特拉維夫和北卡羅萊納州拉里格, July 24, 2020 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (Nasdaq: RDHL)（簡稱 RedHill 或「該公司」）是一家專門生物製藥公司，今天宣佈從墨西哥聯邦防止衛生風險保護委員會 (COFEPRIS) 獲批臨床試驗授權 (CTA) 申請，並向巴西健康管理機構 (ANVISA) 申請，以展開第 2/3 期臨床研究，以評估將 opaganib (Yeliva®, ABC294640)1 用於嚴重 SARS-CoV-2 感染（COVID-19 病因）及肺炎的住院患者。RedHill 對本研究的 CTA 申請已在英國和俄羅斯獲得批准，而類似申請正在意大利接受審查，並計劃將研究擴展至更多國家。RedHill 臨床事務副總裁 Aida Bibliowicz 說：「我們正在迅速推進 COVID-19 的第 2/3 期計劃，並繼續將研究擴展到確診個案大幅增長的其他國家。本研究現已在英國和俄羅斯獲得批准，並有望在未來幾週內獲得其他國家的批准，因此預計在本月底納入患者。同時，正在美國進行的 opaganib 第 2 期研究已取得良好進展。如結果成功，我們的目標是編制臨床數據集，以支持今年第四季可能進行的緊急使用授權申請。」這項多中心、隨機、雙盲、平行組、安慰劑對照的第 2/3 期研究 (NCT04467840) 旨在納入多達 270 名需要住院和補充氧氣治療的嚴重 COVID-19 肺炎患者。受試者將以 1:1 的比例隨機分配接受...

2/3期研究在巴西和墨西哥启动 使用opaganib治疗新冠肺炎重症患者的全球2/3期研究已在英国和俄罗斯获得批准 患者招募计划注册计划在本月启动——在最多40处临床地点招募270名受试者 计划于2020年第4季度提交紧急使用授权申请 在美国同时进行的针对重症新冠肺炎的2期研究预计预计将于8月完成以色列特拉维夫和北卡罗来纳州罗利, July 24, 2020 (GLOBE NEWSWIRE) — 特种生物制药企业RedHill Biopharma Ltd.（纳斯达克：RDHL）（以下称“RedHill”或该“公司”）今天宣布，该公司已向墨西哥卫生风险防范联合委员会（COFEPRIS）提交了一份临床试验申请（CTA），并向巴西卫生监管局（ANVISA）提出了2/3阶段临床研究CTA申请，以评估opaganib（Yeliva®，ABC294640）1对重度SARS-CoV-2（新型冠状病毒）感染（新冠肺炎的致病原因）和肺炎住院患者的疗效。RedHill关于这项研究的CTA申请已在英国和俄罗斯获得批准，类似申请正在意大利接受审批，此外还有计划将这项研究扩展到更多国家。“我们正在快速推进针对新冠肺炎的2/3期计划，并继续将这项研究扩展到已诊断病例大幅增长的其他国家。这项研究目前已在英国和俄罗斯获得批准，而且预计在未来几周将获更多批准，因此患者招募工作计划在本月晚些时候开始，” RedHill临床事务副总裁Aida Bibliowicz介绍说，“同时，正在美国进行的opaganib第二阶段研究取得了良好进展。如果获得成功，我们的目标是编制临床数据集，以支持可能在今年第四季度提交的紧急使用授权申请。”这是一项多中心、随机、双盲、平行、安慰剂对照的2/3期研究（NCT04467840），计划招募270名需要住院治疗和辅助供氧的新冠肺炎重症患者参与试验。受试者将以1:1的比例随机分组，接受opaganib或安慰剂用药，并按医护标准接受治疗。该研究的主要终点是评估在第14天时需要插管和呼吸机的患者比例。在大约100名受试者接受主要终点评估之后，一家独立数据安全监测委员会（DSMB）将进行解盲无效中期分析。此外，在美国的一项使用opaganib进行随机、双盲、安慰剂对照2期临床研究（NCT04414618）的受试者招募也正在进行中。这项研究旨在招募40名需要住院治疗和辅助吸氧的新冠肺炎重症患者参与试验，招募预计于八月完成。这次临床试验并非以统计意义为目的。RedHill最近宣布，第一批使用opaganib的新冠肺炎重症患者的治疗结果已公布2。对5例新冠肺炎重症患者的治疗结果分析显示，与同一医院回顾性配对病例对照组的患者相比，接受opaganib体恤用药治疗的患者在临床结果和炎症标志物方面均有显著获益。opaganib治疗组中的所有患者都在无需使用呼吸机的情况下出院，而对应的病例对照组中有33%的患者需要呼吸机。opaganib治疗组的经鼻高量氧疗脱机中位时间减少到10天，而匹配病例对照组则为15天。关于opaganib（ABC294640，Yeliva®）opaganib是一种新的化学体，一种专有的首创性口服鞘氨醇激酶-2（SK2）选择性抑制剂，具有抗肿瘤、抗炎和抗病毒活性，针对多种肿瘤、病毒、炎症和肠道适应症。通过抑制SK2，opaganib可影响与癌细胞生长、病毒复制和病理炎症相关的多种蜂窝路径。opaganib最初由美国Apogee...

Með vísan til 2. kafla útgáfulýsingar skuldabréfaflokksins REG3A 14 1 (IS0000024313) tilkynnist hér með að Reginn atvinnuhúsnæði ehf. hefur nýtt sér ákvæði til uppgreiðslu og hlutagreiðslu skv. lánssamningi við útgefanda og mun útgefandi inna sömu greiðslu af hendi inn á höfuðstól skuldabréfsins á næsta gjalddaga þess 25.08.2020.Samkvæmt lánssamningum skal lántaki tilkynna lánveitanda um fyrirhugaða uppgreiðslu og hlutagreiðslu með a.m.k. 30 daga fyrirvara. Lágmarksgreiðsla umfram greiðsluskyldu er kr. 100.000.000,- í samræmi við skilmála lánsamningsins. Útgefandi mun tilgreina fjárhæð uppgreiðslunnar um leið og frekari upplýsingar berast frá lántaka.  Nánari upplýsingar veitir Þorkell Magnússon forstöðumaður skuldabréfa hjá Júpíter rekstrarfélagi hf. sem er rekstraraðili útgefanda.Sími: 5220110.Netfang: thorkell.magnusson@jupiter.is

DENVER, July 23, 2020 (GLOBE NEWSWIRE) — StoneCastle Financial Corp., (NASDAQ:BANX) (“StoneCastle Financial” or the “Company”), today announced that the Company’s June 30, 2020 Net Asset Value (“NAV”) was $20.27.  The NAV increased $1.27 or 9.06%, after reinvestment of dividends, as compared to the prior quarter-end NAV.StoneCastle Financial will host a conference call for investors and other interested parties beginning at 5:00 p.m. (Eastern Time) on Thursday, August 6, 2020 to discuss the Company’s financial results and investment performance and provide its current views on bank-related assets and the community banking market. The call will be hosted by Sanjai Bhonsle, Chairman and Chief Executive Officer and Patrick Farrell, Chief Financial Officer.The conference call will be accessible by telephone and the internet....

DALLAS, July 23, 2020 (GLOBE NEWSWIRE) — Hallmark Financial Services, Inc. (“Hallmark Financial”) (NASDAQ: HALL) today announced financial results for the first quarter ended March 31, 2020.(1) See “Non-GAAP Financial Measures” belowFirst Quarter 2020 Highlights (all comparisons to same prior year period):Hallmark Financial reported a net combined ratio of 97.6% as compared to 96.5% for the first quarter of 2019.  During the quarter, as previously announced on March 2nd, the Company decided to exit the Binding Primary Auto business.  The combined ratio was negatively impacted by 7.5 points from this discontinued line of business during the quarter. Hallmark Financial saw continued momentum on rate increases, as rates were up 13% for all lines and 16% for the Specialty Commercial Segment.Gross premiums written increased 8% to $201.6...

SAN FRANCISCO, July 23, 2020 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nurix), a company developing targeted protein modulation drugs, today announced the pricing of its initial public offering of 11,000,000 shares of its common stock at a price to the public of $19.00 per share. All of the shares are being offered by Nurix. The shares are expected to begin trading on The Nasdaq Global Market on July 24, 2020 under the symbol “NRIX.” The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Nurix, are expected to be $209 million. In addition, Nurix has granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The offering is...